# A Phase 2a Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis

> **NCT04129489** · PHASE2 · TERMINATED · sponsor: **Stero Biotechs Ltd.** · enrollment: 2 (actual)

## Conditions studied

- Autoimmune Hepatitis

## Interventions

- **DRUG:** Cannabidiol

## Key facts

- **NCT ID:** NCT04129489
- **Lead sponsor:** Stero Biotechs Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-07
- **Primary completion:** 2020-03-01
- **Final completion:** 2020-03-01
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** low recruitment
- **Last updated:** 2020-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04129489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04129489, "A Phase 2a Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04129489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*